ticagrelor + clopidogrel

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Stable Coronary Artery Disease

Conditions

Stable Coronary Artery Disease

Trial Timeline

Apr 1, 2010 → Mar 1, 2011

NCT ID

NCT01118325

About ticagrelor + clopidogrel

ticagrelor + clopidogrel is a phase 2 stage product being developed by AstraZeneca for Stable Coronary Artery Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01118325. Target conditions include Stable Coronary Artery Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04069234	Phase 3	Withdrawn	Sep 15, 2019	Mar 31, 2022	Diabetes Mellitus
NCT03437044	Approved	Completed	Mar 14, 2018	Jun 27, 2020	Diabetes Mellitus, Type 2
NCT02617290	Phase 3	Completed	Jan 9, 2017	Sep 15, 2020	Coronary Artery Disease
NCT02663713	Approved	Completed	Jan 1, 2017	Jun 1, 2017	Myocardial Infarction
NCT02319941	Phase 2	Completed	May 20, 2015	Mar 10, 2017	Acute Coronary Syndrome
NCT02457130	Approved	UNKNOWN	Apr 1, 2015	Feb 1, 2017	Coronary Artery Disease
NCT02379676	Approved	UNKNOWN	Jan 1, 2015	Mar 1, 2017	Endothelial Dysfunction
NCT02121288	Approved	Withdrawn	Dec 1, 2014	Feb 1, 2016	Peripheral Artery Disease
NCT02233790	Approved	UNKNOWN	Dec 1, 2014	Dec 1, 2016	Myocardial Infarction
NCT02618733	Pre-clinical	Completed	Dec 1, 2014	Dec 31, 2016	Acute Coronary Syndrome
NCT02052635	Approved	Terminated	Sep 1, 2014	Apr 1, 2015	Non-ST Elevation Acute Coronary Syndrome
NCT01826175	Approved	Withdrawn	May 1, 2013	May 1, 2014	Acute Coronary Syndrome
NCT01864005	Approved	Completed	May 1, 2013	Mar 1, 2014	Non-ST or ST Elevation Acute Coronary Syndromes
NCT01732822	Phase 3	Completed	Dec 4, 2012	Sep 26, 2016	Peripheral Artery Disease
NCT01706510	Approved	Completed	Dec 1, 2012	Apr 1, 2014	Coronary Artery Disease
NCT01603082	Approved	Completed	Jul 1, 2012	Jun 1, 2014	Acute Coronary Syndrome
NCT01523366	Approved	Completed	Apr 1, 2012	May 1, 2013	Stable Coronary Artery Disease
NCT01523392	Approved	Completed	Mar 1, 2012	Sep 1, 2013	Stable Coronary Artery Disease
NCT01118325	Phase 2	Completed	Apr 1, 2010	Mar 1, 2011	Stable Coronary Artery Disease
NCT00391872	Phase 3	Completed	Oct 1, 2006	Mar 1, 2009	Acute Coronary Syndrome

Competing Products

20 competing products in Stable Coronary Artery Disease

See all competitors

Product	Company	Stage	Hype Score
eFT508 + Avelumab	eFFECTOR Therapeutics	Phase 2	44
Atorvastatin 20mg loading + Atorvastatin 80mg loading	Yuhan	Approved	85
ASP7991	Astellas Pharma	Phase 1	33
Epoetin Alfa + Roxadustat	Astellas Pharma	Phase 3	77
TRC041266 + Placebo	Torrent Pharmaceuticals	Phase 3	77
Evorpacept (ALX148) + Cetuximab + Pembrolizumab	Eli Lilly	Phase 2	52
budesonide/formoterol + formoterol	AstraZeneca	Phase 2	52
Ticagrelor + Clopidogrel + Aspirin	AstraZeneca	Phase 2	52
Inhibition of Platelet Aggregation by "Brilinta"(Ticagrelor)	AstraZeneca	Approved	85
TC-5214 + Placebo	AstraZeneca	Phase 1	33
Ticagrelor + Clopidogrel	AstraZeneca	Approved	85
Ticagrelor + Clopidogrel	AstraZeneca	Approved	85
grapiprant + grapiprant and pembrolizumab	Merck	Phase 1	33
Bevacizumab + Capecitabine + Pembrolizumab	Merck	Phase 2	52
Nicorandil + Standard Treatment	Merck	Approved	85
BPS804 + Placebo	Novartis	Phase 2	52
CLR325	Novartis	Phase 2	52
Erenumab + Placebo	Amgen	Phase 2	51
Ranolazine + Placebo	Gilead Sciences	Approved	84
ranolazine + placebo	Gilead Sciences	Approved	84

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved